Here’s Our Rant About Calithera Biosciences Inc. (CALA) – News Heater
Home  »  Hot Stocks   »  Here’s Our Rant About Calithera Biosciences ...

Here’s Our Rant About Calithera Biosciences Inc. (CALA)

Calithera Biosciences Inc. (NASDAQ:CALA) went down by -15.18% from its latest closing price compared to the recent 1-year high of $2.59. The company’s stock price has collected -20.77% of loss in the last five trading sessions.

Is It Worth Investing in Calithera Biosciences Inc. (NASDAQ :CALA) Right Now?

Plus, the 36-month beta value for CALA is at 1.62.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


CALA currently public float of 65.30M and currently shorts hold a 3.88% ratio of that float. Today, the average trading volume of CALA was 2.28M shares.

CALA’s Market Performance

CALA stocks went down by -20.77% for the week, with a monthly drop of -39.21% and a quarterly performance of -63.49%, while its annual performance rate touched -89.77%. The volatility ratio for the week stands at 11.03% while the volatility levels for the past 30 days are set at 11.44% for Calithera Biosciences Inc.. The simple moving average for the period of the last 20 days is -32.01% for CALA stocks with a simple moving average of -82.39% for the last 200 days.

Analysts’ Opinion of CALA

Jefferies, on the other hand, stated in their research note that they expect to see CALA reach a price target of $6. The rating they have provided for CALA stocks is “Buy” according to the report published on March 27th, 2020.

H.C. Wainwright gave a rating of “Buy” to CALA, setting the target price at $7 in the report published on November 19th of the previous year.

CALA Trading at -49.67% from the 50-Day Moving Average

After a stumble in the market that brought CALA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.26% of loss for the given period.

Volatility was left at 11.44%, however, over the last 30 days, the volatility rate increased by 11.03%, as shares sank -37.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -61.33% lower at present.

During the last 5 trading sessions, CALA fell by -20.77%, which changed the moving average for the period of 200-days by -90.26% in comparison to the 20-day moving average, which settled at $0.2889. In addition, Calithera Biosciences Inc. saw -69.84% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CALA starting from Orford Keith, who sale 48,190 shares at the price of $0.88 back on Nov 11. After this action, Orford Keith now owns 66,094 shares of Calithera Biosciences Inc., valued at $42,407 using the latest closing price.

Molineaux Susan, the PRESIDENT & CEO of Calithera Biosciences Inc., purchase 100,000 shares at $0.85 during a trade that took place back on Nov 10, which means that Molineaux Susan is holding 557,188 shares at $84,670 based on the most recent closing price.

Stock Fundamentals for CALA

Equity return is now at value -177.10, with -126.70 for asset returns.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam